These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33496819)

  • 1. Index60 as an additional diagnostic criterion for type 1 diabetes.
    Redondo MJ; Nathan BM; Jacobsen LM; Sims E; Bocchino LE; Pugliese A; Schatz DA; Atkinson MA; Skyler J; Palmer J; Geyer S; Sosenko JM;
    Diabetologia; 2021 Apr; 64(4):836-844. PubMed ID: 33496819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.
    Nathan BM; Boulware D; Geyer S; Atkinson MA; Colman P; Goland R; Russell W; Wentworth JM; Wilson DM; Evans-Molina C; Wherrett D; Skyler JS; Moran A; Sosenko JM;
    Diabetes Care; 2017 Nov; 40(11):1494-1499. PubMed ID: 28860125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.
    Jacobsen LM; Bundy BN; Ismail HM; Clements M; Warnock M; Geyer S; Schatz DA; Sosenko JM
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2784-2792. PubMed ID: 35880956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.
    Sosenko JM; Skyler JS; DiMeglio LA; Beam CA; Krischer JP; Greenbaum CJ; Boulware D; Rafkin LE; Matheson D; Herold KC; Mahon J; Palmer JP; ;
    Diabetes Care; 2015 Feb; 38(2):271-6. PubMed ID: 25519451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.
    Jacobsen LM; Bocchino L; Evans-Molina C; DiMeglio L; Goland R; Wilson DM; Atkinson MA; Aye T; Russell WE; Wentworth JM; Boulware D; Geyer S; Sosenko JM
    Diabetologia; 2020 Mar; 63(3):588-596. PubMed ID: 31768570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes.
    Nathan BM; Redondo MJ; Ismail H; Jacobsen L; Sims EK; Palmer J; Skyler J; Bocchino L; Geyer S; Sosenko JM
    Diabetes Care; 2022 Feb; 45(2):311-318. PubMed ID: 34853027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance.
    Redondo MJ; Sosenko J; Libman I; McVean JJF; Tosur M; Atkinson MA; Becker D; Geyer S
    J Clin Endocrinol Metab; 2020 May; 105(5):1629-40. PubMed ID: 31867614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.
    Baidal DA; Warnock M; Xu P; Geyer S; Marks JB; Moran A; Sosenko J; Evans-Molina C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3273-e3280. PubMed ID: 35524749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.
    Evans-Molina C; Sims EK; DiMeglio LA; Ismail HM; Steck AK; Palmer JP; Krischer JP; Geyer S; Xu P; Sosenko JM;
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.
    Bediaga NG; Li-Wai-Suen CSN; Haller MJ; Gitelman SE; Evans-Molina C; Gottlieb PA; Hippich M; Ziegler AG; Lernmark A; DiMeglio LA; Wherrett DK; Colman PG; Harrison LC; Wentworth JM
    Diabetologia; 2021 Nov; 64(11):2432-2444. PubMed ID: 34338806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA.
    Martinez MM; Salami F; Larsson HE; Toppari J; Lernmark Å; Kero J; Veijola R; Koskenniemi JJ; Tossavainen P; Lundgren M; Borg H; Katsarou A; Maziarz M; Törn C;
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00198. PubMed ID: 33855205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.
    Simmons KM; Sosenko JM; Warnock M; Geyer S; Ismail HM; Elding Larsson H; Steck AK
    J Clin Endocrinol Metab; 2020 Nov; 105(11):e4094-101. PubMed ID: 32844178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.
    Sosenko JM; Krischer JP; Palmer JP; Mahon J; Cowie C; Greenbaum CJ; Cuthbertson D; Lachin JM; Skyler JS;
    Diabetes Care; 2008 Mar; 31(3):528-33. PubMed ID: 18000175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening.
    Sims EK; Cuthbertson D; Felton JL; Ismail HM; Nathan BM; Jacobsen LM; Paprocki E; Pugliese A; Palmer J; Atkinson M; Evans-Molina C; Skyler JS; Redondo MJ; Herold KC; Sosenko JM
    Diabetes Care; 2022 Dec; 45(12):2982-2990. PubMed ID: 36326757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting progression to diabetes in islet autoantibody positive children.
    Steck AK; Dong F; Frohnert BI; Waugh K; Hoffman M; Norris JM; Rewers MJ
    J Autoimmun; 2018 Jun; 90():59-63. PubMed ID: 29395739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.
    Ismail HM; Cleves MA; Xu P; Libman IM; Becker DJ; Marks JB; Skyler JS; Palmer JP; Sosenko JM;
    Diabetes Care; 2020 Nov; 43(11):2668-2674. PubMed ID: 32900788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
    Fouts A; Pyle L; Yu L; Miao D; Michels A; Krischer J; Sosenko J; Gottlieb P; Steck AK;
    Diabetes Care; 2016 Oct; 39(10):1738-44. PubMed ID: 27456836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.
    Bogun MM; Bundy BN; Goland RS; Greenbaum CJ
    Diabetes Care; 2020 Aug; 43(8):1836-1842. PubMed ID: 32457058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.
    Ismail HM; Xu P; Libman IM; Becker DJ; Marks JB; Skyler JS; Palmer JP; Sosenko JM;
    Diabetologia; 2018 Jan; 61(1):84-92. PubMed ID: 28956083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.
    Ismail HM; Cuthbertson D; Gitelman SE; Skyler JS; Steck AK; Rodriguez H; Atkinson M; Nathan BM; Redondo MJ; Herold KC; Evans-Molina C; DiMeglio LA; Sosenko J;
    Diabetes Care; 2022 Oct; 45(10):2264-2270. PubMed ID: 35998266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.